Esthesioneuroblastoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 61: Line 61:
|}
|}


The various features of histopathological grading according to Hyams is shown below in a tabular form:<ref>Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.</ref>
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center
|valign=top|
|valign=top|

Revision as of 04:12, 27 January 2016

Esthesioneuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Esthesioneuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esthesioneuroblastoma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esthesioneuroblastoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esthesioneuroblastoma pathophysiology

CDC on Esthesioneuroblastoma pathophysiology

Esthesioneuroblastoma pathophysiology in the news

Blogs on Esthesioneuroblastoma pathophysiology

Directions to Hospitals Treating Esthesioneuroblastoma

Risk calculators and risk factors for Esthesioneuroblastoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Genes involved in the pathogenesis of esthesioneuroblastoma include chromosomal gains in 7q11 and 20q and deletions in 2q, 5q, 6p, 6q, and 18q. On gross pathology, soft and hemorrhagic, polypoid appearance, and rich and fragile vascular supply of the tumor are characteristic findings of esthesioneuroblastoma. On microscopic histopathological analysis, arrangements of cells into rosettes or pseudorosettes are characteristic findings of esthesioneuroblastoma.[1][2][3][4][5][6][7]

Pathophysiology

Gross Pathology

  • On gross examination, biopsy material from olfactory neuroblastoma is soft and hemorrhagic.
  • Resection specimens may show a polypoid appearance.
  • The vascular supply of the tumor is rich and fragile, accounting for the hemorrhagic gross appearance.

Microscopic Pathology

  • Olfactory neuroblastomas are of neural crest cell origin. They are mulilobulated pink-grey tumors.
  • Histology demonstrates variable differentiation, from well formed neural tissue to undifferentiated neuroblasts with pseudorosette formation.[1][2]
  • Microscopically, the tumor grows beneath the surface respiratory epithelium and may produce focal ulceration.
  • Esthesioneuroblastomas (ENBs) can display various histologic presentations.
    • The hallmark of well-differentiated esthesioneuroblastoma is arrangements of cells into rosettes or pseudorosettes.
    • True rosettes (Flexner-Wintersteiner rosettes) refer to a ring of columnar cells circumscribing a central oval-to-round space, which appears clear on traditional pathologic sections.
    • Pseudorosettes (Homer-Wright rosettes) are characterized by a looser arrangement and the presence of fibrillary material within the lumen.
  • In low-grade or well-differentiated lesions, the growth pattern is lobulated with transitions into sheets or discrete nests of tumor cells, which are small and round with high nuclear cytoplasmic ratios.[8][4]
  • In well-differentiated tumors, the nuclei show uniform chromatin distribution with small unremarkable nucleoli. The nuclei become progressively more pleomorphic, with prominent nucleoli and coarse chromatin clumping, with increasing tumor grade. The stroma in well-differentiated tumors is distinctly fibrillary, reflecting the neuronal processes made by the tumor cells. This stroma decreases in quantity as the tumor becomes less well-differentiated. Mitoses and areas of necrosis also become more frequent with increasing tumor grade.
  • In one-half of olfactory neuroblastomas, Homer Wright pseudorosettes, which are composed of tumor cells surrounding a center of pink fibrillary material are seen.
  • In higher grade tumors, true (Flexner type) rosettes, composed of tumor cells surrounding a central lumen are seen.
  • Vascular or lymphatic invasion, necrosis, and dystrophic calcification are more common with increasing tumor grade.
  • A few admixed ganglion cells may be present, on rare instances.
  • Electron microscopy of olfactory neuroblastomas demonstrates numerous axonal-type cytoplasmic processes, which contain neurotubules, neurofilaments, and dense-core neurosecretory granules (100 to 200 nm in diameter). The S100 immunoreactivity corresponds to Schwann cells enveloping axonal processes and cell bodies.[9][4]

Genetics

  • A tool called array comparative genomic hybridization was applied to the analysis of esthesioneuroblastomass. Although many alterations were identified by this study, chromosomal gains in 7q11 and 20q and deletions in 2q, 5q, 6p, 6q, and 18q have been confirmed by at least two other studies.
  • Although still investigational, the demonstration of human achaete-scute homologue (HASH1) gene expression, could become the diagnostic procedure of choice. The HASH1 gene is expressed in immature olfactory cells and is involved in olfactory neuronal differentiation; therefore, it could be useful in distinguishing esthesioneuroblastoma from other poorly differentiated small blue cell tumors.[5][6][7]


The Hyams histologic grading system grades tumors from I to IV based upon pathologic features such as mitotic activity and necrosis. [10]

Grade Features
Grade I
  • Grade I tumors are characterized by a prominent fibrillary matrix, tumor cells with uniform nuclei, absent mitotic activity, and necrosis.
Grade II
  • Grade II tumors have some fibrillary matrix and exhibit moderate nuclear pleomorphism with son=me mitotic activity. There is no necrosis
Grade III
  • Grade III tumors have minimal fibrillary matrix and Flexner type rosettes are present. There is more prominent mitotic activity and nuclear pleomorphism, and some necrosis may be seen
Grade IV
  • Grade IV tumors have no fibrillary matrix or rosettes and show marked nuclear pleomorphism and increased mitotic activity with frequent necrosis

The various features of histopathological grading according to Hyams is shown below in a tabular form:[11]

Grade Mitotic Index Nuclear Polymorphism Fibrillary Matrix Rosettes Necrosis Lobular Architecture Preservation
Grade I

Zero

None

Prominent

Homer Wright Rosettes

None

+

Grade II

Low

Low

Present

Homer Wright Rosettes

None

+

Grade III

Moderate

Moderate

Low

Flexner-Wintersteiner rosettes

Rare

+/-

Grade IV

High

High

Absent

None

Frequent

+/-

Associated Conditions

References

  1. 1.0 1.1 Esthesioneuroblastoma. Radiopedia(2015) http://radiopaedia.org/articles/olfactory-neuroblastoma Accessed on January 25, 2016
  2. 2.0 2.1 Esthesioneuroblastoma. Libre pathology(2015) http://librepathology.org/wiki/index.php/Olfactory_neuroblastoma Accessed on January 25, 2015
  3. Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.
  4. 4.0 4.1 4.2 Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, Harner SG; et al. (1995). "Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study". Cancer. 76 (1): 4–19. PMID 8630875.
  5. 5.0 5.1 Guled M, Myllykangas S, Frierson HF, Mills SE, Knuutila S, Stelow EB (2008). "Array comparative genomic hybridization analysis of olfactory neuroblastoma". Mod Pathol. 21 (6): 770–8. doi:10.1038/modpathol.2008.57. PMID 18408657.
  6. 6.0 6.1 Mhawech P, Berczy M, Assaly M, Herrmann F, Bouzourene H, Allal AS; et al. (2004). "Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract". Am J Clin Pathol. 122 (1): 100–5. doi:10.1309/QD0K-9Q1J-BH6B-5GQQ. PMID 15272537.
  7. 7.0 7.1 Carney ME, O'Reilly RC, Sholevar B, Buiakova OI, Lowry LD, Keane WM; et al. (1995). "Expression of the human Achaete-scute 1 gene in olfactory neuroblastoma (esthesioneuroblastoma)". J Neurooncol. 26 (1): 35–43. PMID 8583243.
  8. Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.
  9. Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.
  10. Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.
  11. Hyams, V. J. (1988). Tumors of the upper respiratory tract and ear. Washington, D.C.: Armed Forces Institute of Pathology.

Template:Central nervous system tumors

Template:WH Template:WS